CNS Pharmaceuticals, Inc. financial data

Symbol
CNSP on Nasdaq
Location
2100 West Loop South, Suite 900, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 554 % +903%
Debt-to-equity 21.5 %
Return On Equity -130 % -119%
Return On Assets -107 % +79.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 620K shares -98.9%
Common Stock, Shares, Outstanding 575K shares -98.3%
Entity Public Float 8.78M USD 0%
Common Stock, Value, Issued 574 USD -98.3%
Weighted Average Number of Shares Outstanding, Basic 559K shares +1427%
Weighted Average Number of Shares Outstanding, Diluted 559K shares +1427%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.1M USD -32.8%
General and Administrative Expense 5.1M USD +1.55%
Operating Income (Loss) -13.2M USD +22.7%
Nonoperating Income (Expense) 129K USD +426%
Net Income (Loss) Attributable to Parent -13.1M USD +23.4%
Earnings Per Share, Basic 5.17K USD/shares +96.2%
Earnings Per Share, Diluted 5.17K USD/shares +96.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.86M USD +41.5%
Assets, Current 11.4M USD +54.2%
Property, Plant and Equipment, Net 3.11K USD +10.9%
Assets 11.9M USD +60.2%
Accounts Payable, Current 3.57M USD +627%
Accrued Liabilities, Current 260K USD -5.94%
Liabilities, Current 1.96M USD -51.7%
Liabilities 1.96M USD -51.7%
Retained Earnings (Accumulated Deficit) -94.3M USD -16.1%
Stockholders' Equity Attributable to Parent 9.91M USD +196%
Liabilities and Equity 11.9M USD +60.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.24M USD -1.56%
Net Cash Provided by (Used in) Financing Activities 9.83M USD +184%
Common Stock, Shares Authorized 25M shares -91.7%
Common Stock, Shares, Issued 575K shares -98.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.86M USD +41.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 6.21K USD -6.29%
Deferred Tax Assets, Valuation Allowance 15.3M USD +19.9%
Depreciation 1.1K USD +34.5%
Deferred Tax Assets, Operating Loss Carryforwards 7.92M USD +18.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 417K shares -91.7%
Additional Paid in Capital 104M USD +23.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 15K USD +51.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%